Grazoprevir/elbasvir fixed-dose combination for hepatitis C.
N Gamal, P Andreone
págs. 377-386
Trends and challenges in immuno-oncology trials.
B. J. Kiernan
págs. 387-394
Increasing precision in medicine - tackling the bottleneck of variant interpretation.
Brian M. Baker
págs. 395-398
Precision Medicine Intelligence - evidence scoring evaluating the clinical actionability of BRAF V600E in multiple non-melanoma solid tumors.
A. Crescenzo
págs. 399-406
Highlights from the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) (June 3-7, 2016 – Chicago, Illinois, USA).
Alexandra Kibble, A Al-Shamahi, K. Kuennemann, A. F. Marques, L. Tremosa, Benton P. Cole
págs. 407-424
New product intros (atezolizumab, evogliptin hydrochloride/metformin [new combination], lonoctocog alfa, maxacalcitol/betamethasone butyrate propionate [new combination], obeticholic acid, Flucelvax Quadrivalent).
págs. 425-426
© 2001-2024 Fundación Dialnet · Todos los derechos reservados
Coordinado por: